Crescent Biopharma Inc(CBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CBIO Crescent Biopharma Inc

未开盘 06-09 16:00:00 EDT

18.00

+0.72

+4.17%

盘后18.00

+0.000.00%

16:37 EDT

最高18.23	最低17.25	成交量12.62万
今开17.38	昨收17.28	日振幅5.67%
总市值4.96亿	流通市值1.96亿	总股本2,756万
成交额224.59万	换手率1.16%	流通股本1,087万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CBIO","market":"US","secType":"STK","nameCN":"Crescent Biopharma Inc","latestPrice":18,"timestamp":1781035200000,"preClose":17.28,"halted":0,"volume":126189,"hourTrading":{"tag":"盘后","latestPrice":18,"preClose":18,"latestTime":"16:37 EDT","volume":153,"amount":2768.67,"timestamp":1781037438262,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.041666666666666595,"floatShares":10871000,"shares":27556800,"eps":-5.878,"marketStatus":"未开盘","change":0.72,"latestTime":"06-09 16:00:00 EDT","open":17.38,"high":18.23,"low":17.25,"amount":2245947.533487,"amplitude":0.056713,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.878,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781078400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1389330000000,"exchange":"NASDAQ","adjPreClose":17.28,"postHourTrading":{"tag":"盘后","latestPrice":18,"preClose":18,"latestTime":"16:37 EDT","volume":153,"amount":2768.67,"timestamp":1781037438262,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.537886,"impliedVol":2.2495,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/CBIO","defaultTab":"news","newsList":[{"id":"1168449350","title":"Crescent Biopharma 将在2026年美国临床肿瘤学会年会上公布CR-001的Ascend研究进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1168449350","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168449350?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:30","pubTimestamp":1779399031,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc 宣布，将在即将到来的2026年美国临床肿瘤学会（ASCO）年会上，就其PD-1 x VEGF双特异性抗体CR-001的Ascend研究，进行“试验进展”报告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115555630","title":"Crescent Biopharma Inc 提交转售说明书 股东拟出售最多1960万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1115555630","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115555630?lang=zh_cn&edition=full","pubTime":"2026-03-18 04:26","pubTimestamp":1773779173,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc 已向美国证券交易委员会（SEC）提交了一份转售说明书文件。根据该文件，公司部分持股股东计划出售最多1960万股普通股。\n此次转售的股票全部由现有持股人提供，公司本身不会通过本次出售获得任何融资收益。该文件为股东在公开市场转售其持有的公司股份提供了必要的法律依据和程序框架。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616308879","title":"Crescent Biopharma, Inc.盘中异动 早盘股价大跌5.27%报10.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616308879","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616308879?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:35","pubTimestamp":1772548510,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日22时35分，Crescent Biopharma, Inc.股票出现波动，股价快速下跌5.27%。Crescent Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为1.03%。Crescent Biopharma, Inc.公司简介：Crescent Biopharma Inc 是一家生物制药公司，以CR-001为先导，开发新型治疗实体肿瘤的药物。Crescent相信CR-001有潜力提供比派姆单抗更好的临床疗效和安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603032235119542d362&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603032235119542d362&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166328521","title":"Crescent Biopharma Inc：2025年确认收入源于科伦生物科技就Cr-001许可协议支付的2000万美元预付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1166328521","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166328521?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:39","pubTimestamp":1772109577,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc近日披露，其2025年财报中确认的特定收入，实质来源于科伦生物科技（Kelun-Biotech）根据双方就核心资产Cr-001达成的授权协议所支付的一笔高达2000万美元的预付款项。这一财务安排凸显了Cr-001项目的商业价值与合作伙伴的认可。该笔资金的确认严格遵循相关会计准则，体现了授权交易对Crescent Biopharma短期财务表现的直接贡献。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133923651","title":"Crescent Biopharma公布2025财年第四季度及全年业绩与近期业务亮点","url":"https://stock-news.laohu8.com/highlight/detail?id=1133923651","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133923651?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:34","pubTimestamp":1772109243,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc（简称Crescent Biopharma）已正式发布其2025财年第四季度及全年的财务业绩报告，并同步披露了公司近期的关键业务进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185637266","title":"Crescent Biopharma Inc：Ascend试验领跑，公司四大临床项目预计2026年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1185637266","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185637266?lang=zh_cn&edition=full","pubTime":"2026-02-18 20:32","pubTimestamp":1771417942,"startTime":"0","endTime":"0","summary":"生物制药企业Crescent Biopharma Inc近日披露其研发管线进展，旗下四大临床项目预计将于2026年陆续启动。其中，名为\"Ascend\"的临床试验将率先拉开序幕，成为该公司产品组合中首个进入临床阶段的项目。\n这一规划标志着Crescent Biopharma Inc在创新疗法开发领域迈出关键一步。通过系统性地推进多项临床试验，公司旨在加速核心产品的转化进程，为未来市场布局奠定基础。分析人士指出，此类阶段性突破往往能为生物科技企业创造显著估值弹性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125295470","title":"Crescent Biopharma 宣布首位患者接受Ascend I/II期临床试验中Cr-001治疗晚期实体瘤的给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1125295470","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125295470?lang=zh_cn&edition=full","pubTime":"2026-02-18 20:32","pubTimestamp":1771417938,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc (简称Crescent Biopharma) 已宣布，其针对晚期实体瘤的创新药物Cr-001，在名为Ascend的I/II期临床试验中，完成了对首位患者的首次给药。这一重要进展标志着该候选疗法正式进入临床评估阶段，为后续研究奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610148665","title":"Crescent Biopharma, Inc.盘中异动 大幅下挫7.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610148665","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610148665?lang=zh_cn&edition=full","pubTime":"2026-02-09 22:51","pubTimestamp":1770648701,"startTime":"0","endTime":"0","summary":"北京时间2026年02月09日22时51分，Crescent Biopharma, Inc.股票出现异动，股价大幅下挫7.36%。Crescent Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.07%。Crescent Biopharma, Inc.公司简介：Crescent Biopharma Inc 是一家生物制药公司，以CR-001为先导，开发新型治疗实体肿瘤的药物。CR-001是一种新的分子实体，旨在复制ivonescimab的功能特性，ivonescimab是一种由Akeso Biopharma和Summit Therapeutics开发的合作双特异性抗PD -1/抗VEGF抗体，在与Keytruda头对头的3期临床试验中对非小细胞肺癌提供了更高的疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209225141a6e69bc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209225141a6e69bc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104771630","title":"Crescent Biopharma合作伙伴科伦生物科技获中国NMPA批准CR-003 (SKB105)新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1104771630","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104771630?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:09","pubTimestamp":1767614979,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc宣布，其合作伙伴科伦生物科技已正式获得中国国家药品监督管理局（NMPA）对其创新药物CR-003（研发代号SKB105）的新药临床试验申请批准。这一重要进展标志着该药物在中国进入临床开发阶段的关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158200264","title":"新闻稿：Crescent Biopharma公布诱导奖励授予情况","url":"https://stock-news.laohu8.com/highlight/detail?id=1158200264","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158200264?lang=zh_cn&edition=full","pubTime":"2025-12-19 05:18","pubTimestamp":1766092728,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2025年12月18日-- Crescent Biopharma, Inc.，一家致力于快速推进癌症患者下一波治疗方案的生物技术公司，今天宣布其独立董事会批准向三名非执行员工授予总计129,626股公司普通股的期权作为《Crescent Biopharma, Inc. 2025就业诱导激励奖励计划》下的股权诱导奖励。该期权于2025年12月13日批准，2025年12月15日授予，并且对于每位员工接受Crescent的工作至关重要，符合纳斯达克上市规则5635。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2379512739","title":"凯赛生物：截至10月31日已回购54.9236万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2379512739","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2379512739?lang=zh_cn&edition=full","pubTime":"2023-10-31 18:12","pubTimestamp":1698747120,"startTime":"0","endTime":"0","summary":"证券日报网讯 10月31日晚间，凯赛生物发布公告称，截至2023年10月31日，公司通过上海证券交易所交易系统以集中竞价交易方式回购公司股份54.9236万股，占公司总股本58337.8039万股的比例为0.0941%。回购成交的最高价为57.37元/股，最低价为52.90元/股，支付的资金总额人民币3057.0741万元（不含印花税、交易佣金等交易费用）。（编辑 何帆）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103118311783989b56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103118311783989b56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688065","BK0208","CBIO","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2379198955","title":"凯赛生物：累计回购约55万股 占比0.0941%","url":"https://stock-news.laohu8.com/highlight/detail?id=2379198955","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2379198955?lang=zh_cn&edition=full","pubTime":"2023-10-31 17:37","pubTimestamp":1698745056,"startTime":"0","endTime":"0","summary":"凯赛生物（SH 688065，收盘价：53.11元）10月31日晚间发布公告称，截至2023年10月31日，公司通过上海证券交易所交易系统以集中竞价交易方式回购公司股份约55万股，占公司总股本约5.83亿股的比例为0.0941%。2022年1至12月份，凯赛生物的营业收入构成为：合成生物材料行业占比95.55%。凯赛生物的董事长、总裁均是XIUCAI LIU(刘修才)，男，66岁，学历背景为博士。截至发稿，凯赛生物市值为310亿元。文章来源：每日经济新闻原标题：凯赛生物：累计回购约55万股，占比0.0941%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103117393083d61d06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103117393083d61d06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","688065","CBIO","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2379589096","title":"Catalyst Biosciences Inc盘中异动 大幅上涨7.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2379589096","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2379589096?lang=zh_cn&edition=full","pubTime":"2023-10-30 21:30","pubTimestamp":1698672625,"startTime":"0","endTime":"0","summary":"北京时间2023年10月30日21时30分，Catalyst Biosciences Inc股票出现波动，股价急速拉升7.88%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体涨幅为0.00%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时30分，《凯赛生物2023年前三季度净利3.14亿 同比减少35.44%》资讯为影响Catalyst Biosciences Inc的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310302130258475f4fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310302130258475f4fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2379304977","title":"凯赛生物2023年前三季度净利3.14亿 同比减少35.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2379304977","media":"挖贝网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2379304977?lang=zh_cn&edition=full","pubTime":"2023-10-30 19:01","pubTimestamp":1698663690,"startTime":"0","endTime":"0","summary":"挖贝网2023年10月30日，凯赛生物 近日发布2023年前三季度报,报告期内，公司实现营业收入1,565,490,018.66元,同比减少14.81%；归属于上市公司股东的净利润313,885,180.71元，同比减少35.44%。报告期内研发费用126,413,295.65元，上年同期134,754,753.10元，同比减少6.19%。挖贝网资料显示，凯赛生物的主要业务为新型生物基材料的研发、生产及销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019034483d2d8f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019034483d2d8f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","688065","CBIO","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2379307906","title":"凯赛生物：2023年前三季度净利润约3.14亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2379307906","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2379307906?lang=zh_cn&edition=full","pubTime":"2023-10-30 18:57","pubTimestamp":1698663430,"startTime":"0","endTime":"0","summary":"凯赛生物（SH 688065，收盘价：53.78元）10月30日晚间发布三季度业绩公告称，2023年前三季度营收约15.65亿元，同比减少14.81%；归属于上市公司股东的净利润约3.14亿元，同比减少35.44%。2022年1至12月份，凯赛生物的营业收入构成为：合成生物材料行业占比95.55%。凯赛生物的董事长、总裁均是XIUCAI LIU(刘修才)，男，66岁，学历背景为博士。截至发稿，凯赛生物市值为314亿元。文章来源：每日经济新闻原标题：凯赛生物：2023年前三季度净利润约3.14亿元","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019100783d2dce7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023103019100783d2dce7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688065","GYRE","CBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2378870508","title":"Catalyst Biosciences Inc盘中异动 早盘急速拉升6.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2378870508","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2378870508?lang=zh_cn&edition=full","pubTime":"2023-10-27 21:43","pubTimestamp":1698414201,"startTime":"0","endTime":"0","summary":"北京时间2023年10月27日21时43分，Catalyst Biosciences Inc股票出现异动，股价大幅拉升6.66%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体跌幅为0.74%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时43分，《年报季·龙头系列 | 凯赛生物：业绩以及经营效率下滑，估值较低》资讯为影响Catalyst Biosciences Inc的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102721432383978a74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102721432383978a74&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CBIO","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2378852295","title":"Catalyst Biosciences Inc盘中异动 大幅拉升7.55%报0.570美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2378852295","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2378852295?lang=zh_cn&edition=full","pubTime":"2023-10-26 21:35","pubTimestamp":1698327329,"startTime":"0","endTime":"0","summary":"北京时间2023年10月26日21时35分，Catalyst Biosciences Inc股票出现波动，股价快速上涨7.55%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体跌幅为0.41%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时35分，《年报季·龙头系列 | 凯赛生物：业绩以及经营效率下滑，估值较低》资讯为影响Catalyst Biosciences Inc的重要信息。凯赛生物2023半年报A股排名1653，较上季度排名提高，较去年同期排名大幅下滑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102621353082ff2eda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102621353082ff2eda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CBIO","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2378041090","title":"Catalyst Biosciences Inc盘中异动 早盘大幅拉升6.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2378041090","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2378041090?lang=zh_cn&edition=full","pubTime":"2023-10-25 21:46","pubTimestamp":1698241612,"startTime":"0","endTime":"0","summary":"北京时间2023年10月25日21时46分，Catalyst Biosciences Inc股票出现异动，股价快速上涨6.68%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体跌幅为0.99%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。消息层面，截至21时46分，《年报季·龙头系列 | 凯赛生物：业绩以及经营效率下滑，估值较低》资讯为影响Catalyst Biosciences Inc的重要信息。凯赛生物2023半年报A股排名1653，较上季度排名提高，较去年同期排名大幅下滑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310252146538396bdb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310252146538396bdb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","CBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2378029061","title":"年报季·龙头系列 | 凯赛生物：业绩以及经营效率下滑，估值较低（2023半年报）","url":"https://stock-news.laohu8.com/highlight/detail?id=2378029061","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2378029061?lang=zh_cn&edition=full","pubTime":"2023-10-25 10:58","pubTimestamp":1698202722,"startTime":"0","endTime":"0","summary":"凯赛生物2023半年报行业排名107，较上季度排名提高，较去年同期排名下滑。四核心财务特征2023半年报凯赛生物净利润2.64亿元，与2022半年报相比，净利润快速下滑。2023半年报凯赛生物经营资产报酬率0.68%。凯赛生物2023半年报经营活动现金净流入3.24亿元，较2023半年报减少0.37亿元，2021年报到本期经营活动累计产生净流入17.22亿元。2023半年报凯赛生物经营活动与投资活动资金缺口5.45亿元较2022半年报减少12.62亿元，缺口迅速缩小。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310251110268221ab37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202310251110268221ab37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688065","GYRE","CBIO","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2377508285","title":"Catalyst Biosciences Inc股价重挫10.84% 市值跌74.44万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2377508285","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2377508285?lang=zh_cn&edition=full","pubTime":"2023-10-24 21:35","pubTimestamp":1698154556,"startTime":"0","endTime":"0","summary":"北京时间2023年10月24日21时35分，Catalyst Biosciences Inc股票出现异动，股价急速下跌10.84%。截至发稿，该股报0.416美元/股，成交量6.7714万股，换手率0.18%，振幅9.33%。Catalyst Biosciences Inc股票所在的生物技术行业中，整体涨幅为0.61%。其相关个股中，联拓生物、Immunitybio Inc、Maia Biotechnology Inc涨幅较大，Transcode Therapeutics Inc、Maia Biotechnology Inc、联拓生物较为活跃，换手率分别为55.27%、18.59%、12.25%，振幅较大的相关个股有Immunitybio Inc、Eiger Biopharmaceuticals Inc、联拓生物，振幅分别为17.53%、15.90%、15.76%。Catalyst Biosciences Inc公司简介：凯赛生物公司是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102421355683965f51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102421355683965f51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBIO","BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.crescentbiopharma.com","stockEarnings":[{"period":"1week","weight":-0.1237},{"period":"1month","weight":-0.0789},{"period":"3month","weight":0.3769},{"period":"6month","weight":0.1925},{"period":"1year","weight":-0.1084},{"period":"ytd","weight":0.457}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":0.0022},{"period":"3month","weight":0.0916},{"period":"6month","weight":0.0751},{"period":"1year","weight":0.2338},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Crescent Biopharma, Inc.于2003年在特拉华州注册成立，该公司的注册地于2025年6月16日从特拉华州变更为开曼群岛。该公司是一家专注于为癌症患者提供变革性疗法的临床阶段生物技术公司。Crescent Biopharma旨在通过两大战略成为领先的肿瘤生物技术公司：首先，开发CR-001，这是一种PD-1 x VEGF双特异性抗体，旨在同时靶向PD-1免疫检查点和血管内皮生长因子(VEGF)，有望取代帕博利珠单抗成为基础治疗药物；其次，构建强大的抗体药物偶联物(ADC)产品组合。该公司计划将CR-001与ADC疗法联合使用，形成协同增效的组合疗法，以期改善多种癌症的治疗效果。CR-001的全球1/2期试验（即ASCEND试验）于2026年2月启动，预计CR-002和CR-003的进一步临床试验也将于同年开始。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.001565},{"month":2,"riseRate":0.615385,"avgChangeRate":0.005722},{"month":3,"riseRate":0.384615,"avgChangeRate":-0.009855},{"month":4,"riseRate":0.461538,"avgChangeRate":-0.042062},{"month":5,"riseRate":0.461538,"avgChangeRate":0.07932},{"month":6,"riseRate":0.307692,"avgChangeRate":-0.033635},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.058163},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.053488},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.058271},{"month":10,"riseRate":0.5,"avgChangeRate":0.107936},{"month":11,"riseRate":0.75,"avgChangeRate":0.290074},{"month":12,"riseRate":0.25,"avgChangeRate":-0.030216}],"exchange":"NASDAQ","name":"Crescent Biopharma Inc","nameEN":"Crescent Biopharma Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Crescent Biopharma Inc(CBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Crescent Biopharma Inc(CBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Crescent Biopharma Inc,CBIO,Crescent Biopharma Inc股票,Crescent Biopharma Inc股票老虎,Crescent Biopharma Inc股票老虎国际,Crescent Biopharma Inc行情,Crescent Biopharma Inc股票行情,Crescent Biopharma Inc股价,Crescent Biopharma Inc股市,Crescent Biopharma Inc股票价格,Crescent Biopharma Inc股票交易,Crescent Biopharma Inc股票购买,Crescent Biopharma Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Crescent Biopharma Inc(CBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Crescent Biopharma Inc(CBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}